- Date: November 10, 2017
GlyCardial Diagnostics, which was founded last September, has raised an investment of €2.4 million from Caixa Capital Risc, with participation from the Healthequity SCR fund. GlyCardial is a spin-off from the Catalan Institute of Cardiovascular Sciences (ICCC), which participated in CaixaImpulse 2015 through the Apo J-Glyc project.
The project was named after the protein identified by the ICCC team as a biomarker for early myocardial ischemia diagnosis, and, as in most heart conditions, quick detection is crucial when treating the disease. Caused by a lack of blood supply in the heart, myocardial ischemia is the most common cardiovascular issue, and if it becomes persistent it can end up causing a heart attack.
Led by Judit Cubedo (CEO) and Lina Badimon (CSO), GlyCardial Diagnostics aims to develop a point-of-care device that can quickly detect abnormal levels of Apo J-Glyc protein in the blood. This device could be used in ambulances for example, and would provide an accurate test to allow healthcare decisions to be made quickly. The funds will allow the company to clinically validate the new blood test and to apply for the CE certification mark over the next three years, which would allow the device to be sold in the European Economic Area.
December 12, 2017
In this short interview, Sergio Escalera, CTO of Care Respite, explains how the project took shape, and goes over the time they spent on the programme.
November 17, 2017
On 10 November, participants pitched their valorisation plans to the CaixaImpulse Valorisation Panel, who will confirm the grants offered to each project. The upcoming months will be devoted to execute the actions included in their respective plans.
November 14, 2017
World Diabetes Day is the largest campaign of its kind to raise awareness of the metabolic disease. CaixaImpulse's APODRUG project aims to develop a new treatment for diabetic patients with an associated fatty liver disease.